Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2C | Q8TBX8 | 18/20 | 1.00 |
| ▸ | TNF | P01375 | 2/20 | 0.71 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900015 | 0.86 | PIP4K2C (1.00) | PIP4K2C | |
| SCHEMBL2369019 | 0.84 | MAPK1 (1.00) | PIP4K2CTNFNOD1MAPK1ALDH1A1 | |
| SCHEMBL3385848 | 0.83 | TNF (0.78) | PIP4K2CTNFNOD1MAPK1ALDH1A1 | |
| SCHEMBL3387453 | 0.83 | TNF (0.78) | PIP4K2CTNFNOD1MAPK1ALDH1A1 | |
| SCHEMBL3387853 | 0.83 | TNF (0.74) | PIP4K2CTNFNOD1MAPK1ALDH1A1 | |
| SCHEMBL903108 | 0.82 | PIP4K2C (0.79) | PIP4K2CALDH1A1 | |
| SCHEMBL903171 | 0.82 | PIP4K2C (0.89) | PIP4K2C | |
| SCHEMBL3381243 | 0.81 | TNF (0.74) | PIP4K2CTNFNOD1MAPK1ALDH1A1 | |
| SCHEMBL903207 | 0.81 | PIP4K2C (1.00) | PIP4K2CALDH1A1 | |
| SCHEMBL2368708 | 0.80 | TNF (0.83) | PIP4K2CTNFNOD1MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012044993-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING OR PREVENTING NEURODEGENERATIVE DISEASES OR DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044993-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING OR PREVENTING NEURODEGENERATIVE DISEASES OR DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-04-05 | — | — | WO | disclosed |